CLINICAL TRIALS PROFILE FOR SAPROPTERIN DIHYDROCHLORIDE

All Clinical Trials for Sapropterin Dihydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00104247 ↗	Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels	Completed	BioMarin Pharmaceutical	Phase 3	2005-03-01	The primary objective of this study is to evaluate the efficacy of Phenoptin™ (sapropterin dihydrochloride) in reducing blood phenylalanine (Phe) levels in subjects with phenylketonuria.
NCT00104260 ↗	Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria	Completed	BioMarin Pharmaceutical	Phase 2	2004-12-01	The primary objective is to evaluate the degree and frequency of response to Phenoptin™ (sapropterin dihydrochloride), as demonstrated by a reduction in blood phenylalanine (Phe) level among subjects with phenylketonuria (PKU) who have elevated Phe levels. A secondary objective of this study is to evaluate the safety of Phenoptin™ treatment in this subject population, and identify individuals in this subject population who respond to Phenoptin™ treatment with a reduction in blood Phe level.
NCT00325962 ↗	A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension	Completed	BioMarin Pharmaceutical	Phase 2	2006-05-01	The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.
NCT00403494 ↗	A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease	Completed	BioMarin Pharmaceutical	Phase 2	2006-12-01	The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).
NCT00435331 ↗	6R-BH4 Pulmonary Arterial Hypertension Study	Completed	BioMarin Pharmaceutical	Phase 1	2008-03-01	The purpose of this study is to determine whether the addition of sapropterin dihydrochloride (6R-BH4) to existing treatment has any effect in patients with pulmonary arterial hypertension (PAH). Patients with PAH have low levels of a substance called nitric oxide (NO). Tetrahydrobiopterin (BH4) is a substance produced by the body that is an essential requirement in the formation of NO. NO is thought to be helpful in keeping blood vessels in the lung healthy. 6R-BH4 is an experimental (unproven) medicine made in the lab that is very much like the BH4 that our own body makes. The researchers are investigating whether 6R-BH4 can be added safely to current treatment for PAH and whether there is any evidence of benefit from its use. The study will take approximately one year to complete from the time recruitment begins. The primary objective of the study is to evaluate the safety of oral 6R-BH4, administered in escalating doses in addition to standard care, in subjects with pulmonary arterial hypertension (PAH). The secondary objective of the study is to evaluate change in biochemical markers of endothelial dysfunction and nitric oxide synthetase activity (coupled and uncoupled) in subjects with PAH receiving escalating doses of oral 6R-BH4 in addition to standard care. The third objective of the study is to evaluate change in biomarkers of disease progression, 6-minute walk (6MW) distance, Borg dyspnea scores, and quality of life (QOL) measures in subjects with PAH receiving escalating doses of oral 6R-BH4 in addition to standard care.

Clinical Trial Conditions for Sapropterin Dihydrochloride

Condition Name

Condition Name for Sapropterin Dihydrochloride
Intervention	Trials
Phenylketonuria	17
Phenylketonurias	2
Autistic Disorder	2
Head and Neck Squamous Cell Carcinoma	1

Condition MeSH

Condition MeSH for Sapropterin Dihydrochloride
Intervention	Trials
Phenylketonurias	20
Hypertension	3
Disease	2
Autistic Disorder	2

Clinical Trial Locations for Sapropterin Dihydrochloride

Trials by Country

Trials by Country for Sapropterin Dihydrochloride
Location	Trials
United States	119
Canada	7
Italy	3
Germany	3
Spain	3

Trials by US State

Trials by US State for Sapropterin Dihydrochloride
Location	Trials
California	10
Texas	8
Pennsylvania	7
Georgia	6
Missouri	6

Clinical Trial Progress for Sapropterin Dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for Sapropterin Dihydrochloride
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	2
Phase 4	2

Clinical Trial Status

Clinical Trial Status for Sapropterin Dihydrochloride
Clinical Trial Phase	Trials
Completed	26
Terminated	4
RECRUITING	3

Clinical Trial Sponsors for Sapropterin Dihydrochloride

Sponsor Name

Sponsor Name for Sapropterin Dihydrochloride
Sponsor	Trials
BioMarin Pharmaceutical	24
Merck KGaA	3
University of Missouri-Columbia	3

Sponsor Type

Sponsor Type for Sapropterin Dihydrochloride
Sponsor	Trials
Other	39
Industry	31
NIH	2

SAPROPTERIN DIHYDROCHLORIDE: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is SAPROPTERIN DIHYDROCHLORIDE?

SAPROPTERIN DIHYDROCHLORIDE (brand name: Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor for the enzyme phenylalanine hydroxylase. It is used primarily to treat phenylketonuria (PKU), a rare metabolic disorder caused by enzyme deficiency leading to elevated phenylalanine levels. SAPROPTERIN enhances residual enzyme activity in some PKU patients, allowing for dietary phenylalanine reduction.

What are the recent updates in clinical trials?

Ongoing and Recent Trials

Trial Identifier	Status	Objective	Population	Key Findings (if available)	Completion Date
NCT04584381	Ongoing	Evaluate efficacy in late-diagnosed PKU	Adolescents and adults	Results pending	December 2023
NCT04139939	Recruiting	Assess SAPROPTERIN in PKU pregnant women	Pregnant women with PKU	Safety data collection	June 2024
NCT03886676	Completed	Long-term safety and effectiveness	Pediatric and adult PKU	No new safety concerns; improved phenylalanine control	August 2022

Clinical Trial Outcomes

• Efficacy: Trials demonstrate SAPROPTERIN can reduce phenylalanine levels by an average of 20-50% in responsive patients.
• Safety: Common adverse events include headache, gastrointestinal discomfort, and rash. Serious adverse events are rare.
• Extended Use: Long-term studies indicate maintained efficacy and tolerability over 3-5 years.

Market Analysis

Current Market Size

• The global PKU treatment market was valued at approximately USD 750 million in 2022.
• SAPROPTERIN accounts for an estimated 50% market share, valued at USD 375 million (2022 figures).

Market Drivers

• Increased diagnosis rates via newborn screening programs.
• Growing approval for use in adults and pregnant women.
• Advances in combination therapies improving treatment responses.

Major Competitors

Drug	Type	Market Share (Estimate)	Approvals	Notes
Kuvan	Sapropterin	50%	Approved in the US, EU, Japan	Leading therapy for responsive PKU
Pegvaliase	Glycerol phenylalanine	30%	Approved in US, EU	For patients unresponsive to sapropterin
Dietary Management	Dietary restriction	20%	Not patentable	Standard care; adjunct therapy

Regulatory Environment

• FDA: Approved Kuvan in 2007 for PKU.
• EMA: Approved in 2008.
• Additional Indications: Expanded approval for adjunctive PKU management and use during pregnancy.

Market Projections

Growth Forecast (2023-2028)

Year	Estimated Market Size (USD)	CAGR	Drivers
2023	USD 400 million	-	Steady adoption, ongoing trials
2024	USD 440 million	10%	Approvals for broader indications
2025	USD 500 million	9%	Emerging combination therapies
2026	USD 560 million	8%	Increase in diagnosed cases
2027	USD 620 million	10%	Novel formulations, expanded indications
2028	USD 680 million	10%	Market penetration in developing regions

Key Market Trends

• Expansion of indications: Potential to treat mild hyperphenylalaninemia and other conditions.
• Patient acceptance: Growing preference for oral pharmacotherapy versus diet restrictions.
• Pricing and reimbursement: Increased coverage may boost accessibility.

Challenges

• The responsive vs. non-responsive patient subgroup limits market size.
• Competition from gene therapies in development.
• Cost considerations, as SAPROPTERIN is priced at approximately USD 80,000 annually per patient in the US.

Regulatory and Commercial Outlook

• Expect continued approval expansions, including for use during pregnancy.
• Potential pipeline additions include novel BH4 formulations and combination regimens.
• Strategic partnerships with health authorities and payer systems remain critical for market expansion.

Key Takeaways

• Clinical evidence confirms SAPROPTERIN's efficacy in reducing phenylalanine levels in responsive PKU patients, with a favorable safety profile.
• The market is mature but growing, driven by increased diagnosis, expanded indications, and patient/preferences shifts.
• Revenue projections suggest sustained growth at a CAGR between 8-10% over the next five years, reaching approximately USD 680 million by 2028.
• Competition from enzyme substitution therapies and gene editing approaches may influence future market dynamics.
• Pricing, reimbursement policies, and regional access will significantly affect market expansion.

Frequently Asked Questions

1. What determines if a PKU patient responds to SAPROPTERIN? Response is gene-specific, usually associated with residual phenylalanine hydroxylase activity. Genetic testing identifies responders.

2. Can SAPROPTERIN be used during pregnancy? Yes, approved for use in pregnant women; data shows efficacy in lowering maternal phenylalanine levels, reducing fetal risk.

3. What are the main safety concerns? Headache, gastrointestinal issues, skin rash. Serious adverse events are rare and mostly related to hypersensitivity.

4. How does SAPROPTERIN compare with enzyme substitution therapies? SAPROPTERIN is oral, suitable for responders. Enzyme therapies, like Pegvaliase, target non-responsive patients and may have different administration profiles and safety profiles.

5. What is the outlook for pipeline developments? Research focuses on combining BH4 with other modalities, gene therapy approaches, and improving response in non-responsive patients.

---

References

[1] U.S. Food and Drug Administration. (2007). Kuvan (sapropterin dihydrochloride) tablets. Retrieved from https://www.fda.gov/

[2] European Medicines Agency. (2008). Kuvan approval summary. Retrieved from https://www.ema.europa.eu/

[3] MarketWatch. (2023). Global Phenylketonuria Treatment Market Size, Share & Trends Report. Retrieved from https://www.marketwatch.com/